Hemogenyx Pharmaceuticals (LSE:HEMO), the London-listed clinical-stage biopharmaceutical company, has signed a Letter of Intent with the National Cancer Centre at Vilnius University Hospital Santaros Klinikos, one of Lithuania's leading academic medical centres.
The collaboration targets FLT3-positive acute myeloid leukaemia and myelodysplastic syndromes, both aggressive blood cancers with high unmet need in relapsed or refractory patients.
It splits into two workstreams: a translational research programme characterising FLT3 expression across genetic subtypes and disease compartments, led by Andrius Žučenka of the hospital, and in-hospital manufacturing of HG-CT-1 for compassionate-use treatment under Lithuania's hospital exemption rules, coordinated by Hemogenyx's Dr Vladislav Sandler with Prof. Laimonas Griškevičius on the clinical side.
Hemogenyx retains full ownership of the intellectual property, know-how and regulatory rights underlying the therapy, while the hospital acts as its local manufacturing and clinical partner, with compensation terms for both parties subject to negotiation in definitive agreements.
The arrangement is separate from a further collaboration under discussion in Estonia, disclosed in September 2025, which the company hopes is nearing finalisation.
"This Letter of Intent... is an important step in bringing our HG-CT-1 CAR-T therapy closer to patients who urgently need new options," said Sandler, adding that the structure "may also open up opportunities to expand the use of our technology for additional indications."
Separately, Hemogenyx said its Phase 1 adult trial of HG-CT-1 in relapsed or refractory AML is preparing to dose the next cohort at a higher level, with patients screened but timing unpredictable, while its newly initiated paediatric trial has identified its first patient for screening.
News Intelligence what this means for the company
Hemogenyx has secured a Letter of Intent with Lithuania's leading academic cancer centre to manufacture and deploy its FLT3-directed CAR-T therapy HG-CT-1 under hospital exemption rules, splitting into translational research and in-hospital compassionate-use treatment while retaining full IP ownership. This expands the company's early-access pathway beyond the Estonia collaboration disclosed in September 2025 and demonstrates clinical traction: the adult Phase 1 trial is preparing to dose at a higher level, and the newly initiated paediatric trial has already identified its first screening candidate.
The Lithuania deal validates Hemogenyx's hospital-exemption manufacturing model and extends its geographic footprint for HG-CT-1 deployment in high-unmet-need blood cancers, while the paediatric trial entry and adult dose escalation readiness signal clinical progress. However, this remains a Letter of Intent—not a binding agreement—and compensation terms are still under negotiation; the investment case hinges on whether these early-access routes translate into regulatory pathway clarity and, ultimately, commercial viability.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
